4,901 trials
Carcinoma, Non-small Cell Lung
Primary: Number of Participants With Dose-Limiting Toxicities (DLT) or DLT-equivalent in Part A, B, C, D and E — 1; 4; 0; 5 Participants
Alzheimer's Disease
Primary: Flortaucipir Imaging (Quantitative) Between Cognitive Groups — 1.0048; 0.971; 0.9731; 0.9357 standardized uptake value ratio (SUVr)
Soft Tissue Sarcoma
Primary: Number of Participants With Olaratumab Dose Limiting Toxicities (DLTs) — 4; 4 Participants
Rheumatoid Arthritis
Primary: Part A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs) — 25.0; 50.0; 37.5; 0 percentage of participants
Alzheimer's Disease
Primary: Test-Retest Reproducibility — 1.342; 1.355 standardized uptake value ratio (SUVr)
Solid Tumor
Primary: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of Entrectinib — 41500; 46600; 43400; 9860 nmol*h/L
Carcinoma, Hepatocellular
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) by Severity as Graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse…
Infections, Bacterial
Primary: Part 1- Period 1: Area Under the Concentration-time Curve From Time 0 (Pre-dose) to Time of the Last Quantifiable Concentration (AUC[0-t]) After Single Dose…
Solid Tumor · Lymphoma, Malignant
Primary: Pharmacokinetics (PK): Area Under the Concentration -Time Curve Over a Dosing Interval at Steady State (AUCt,ss) of Enzastaurin, It's Metabolites and Total Analytes in…
HCV Infection
Primary: Pharmacokinetic (PK) Parameter: AUCtau of Norelgestromin — 13757.4; 14690.4 hours*picogram/milliliter (h*pg/mL)
Migraine
Primary: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Lasmiditan — 362; 426 nanograms per milliliter (ng/mL)
Nalbuphine · Opioid Abuse
Primary: To Identify the Appropriate Low, Intermediarte, and High Doses of Nalbuphine Solution (Part A) to be Administered as Single Doses in the Treatment Phase of the Main…
Healthy Volunteers
Primary: Maximum Observed Concentration (Cmax) of GDC-0134. — 5.56; 4.45; 2.66; 2.68 uM
ALL · B Cell Lymphoma · Leukemia
Primary: Number of Participants Who Received Preparative Chemotherapy Followed by Cluster of Differentiation (CD)19-Chimeric Antigen Receptor (CAR): CD19 CAR T-cells With < Grade…
Progressive Supranuclear Palsy · Corticobasal Degeneration
Primary: Flortaucipir Imaging in PSP, CBD and Healthy Volunteers — 1.17; 1.12; 1.03; 1.15 standardized uptake value ratio (SUVr)